Primary And Secondary Outcomes Of The Women's Ischemia Trial To Reduce Events In Non Obstructive Coronary Artery Disease
Eileen Handberg | University of Florida, Gainesville, Florida

RESULTS: Intensive medical therapy did not significantly reduce serious cardiovascular events in women with INOCA compared to usual care partly due to similar prescribing practices in both groups and the impact of the COVID-19 pandemic.

Video: Harmony Reynolds, MD interviews Eileen Handberg, PhD about the results of the WARRIOR trial.

• University of Florida WARRIOR study site
• ClinicalTrials ID: NCT03417388

Extended Anticoagulant Treatment With a Reduced Versus Full Dose Apixaban in Patients With Cancer-Associated Venous Thromboembolism
Isabelle Mahe | Université Paris Cité, Paris, France

RESULTS: For patients with cancer and a history of VTE, a reduced dose of apixaban was non-inferior to a full dose at preventing recurrent VTE. The reduced dose also resulted in fewer clinically relevant bleeding events over the treatment period.

• API-CAT published in NEJM
• NEJM Editorial: Cancer-Associated Venous Thromboembolism — Beyond 6 Months
• ClinicalTrials ID: NCT03692065

Oral Semaglutide Reduces Cardiovascular Events in People With Type 2 Diabetes With Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial
Darren McGuire | UT Southwestern Medical Center, Dallas, Texas

RESULTS: In individuals with type 2 diabetes and ASCVD, CKD, or both, oral semaglutide significantly reduced MACE compared to placebo without increasing serious adverse events.

• SOUL published in NEJM
• ClinicalTrials ID: NCT03914326

Video: SOUL Commentary with Chiadi Ndumele, MD, PhD, MHS, FAHA(link opens in new window)

Comparative Effectiveness of Mobile Integrated Health Versus a Transitions of Care Coordinator in Patients With Heart Failure: Results From the MIGHTy-Heart Trial
Ruth Masterson Creber | Columbia School of Nursing, New York, New York

RESULTS: There was no significant difference in the outcome of MIH compared to TOCC in reducing 30-day readmissions or health status of heart failure patients.

Video: Clyde Yancy, MD, MSc, FAHA, past president of the American Heart Association, interviews Ruth Masterson Creber, PhD, MSc, RN, FAHA about the results of the MIGHTy-Heart Trial.

• ClinicalTrials ID: NCT04662541

Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF2) Trial
Stefan D. Anker| Berlin Institute of Health-Center for Regenerative Therapies (BCRT), Berlin, Germany

RESULTS: Intravenous FCM therapy did not significantly improve the time to first HF hospitalization or CV death compared to placebo in the total group or the TSAT <20% subset. There was no significant difference between FCM therapy and placebo in total HF hospitalizations.

• ClinicalTrials ID: NCT03036462

Clinical And Echocardiographic Outcomes Among the First 500 Patients Treated With a Dedicated Transcatheter Aortic Valve For Pure Aortic Regurgitation in the Align-AR Clinical Trial
Raj Makkar | Cedars Sinai Medical Center, Los Angeles, CA

RESULTS:The new self-expanding transcatheter aortic valve significantly improved heart function, quality of life, and survival rates, with favorable outcomes in ventricular remodeling.

• ClinicalTrials ID: NCT04415047
• Press release from Jenavalve

Two-Year Outcomes of Transcatheter Tricuspid Valve Edge-to-Edge Repair For Tricuspid Regurgitation: The Triluminate Pivotal Trial
Saibal Kar, Los Robles Health System, Thousand Oaks, CA

RESULTS: In patients with severe tricuspid regurgitation, TEER reduced heart failure hospitalizations and improved quality of life without increasing mortality compared to medical therapy alone.

• ClinicalTrials ID: NCT03904147
• TRILUMINATE Pivotal 1-Year Outcomes in JACC

Clopidogrel Versus Aspirin For Long-Term Maintenance Monotherapy in Patients With High Ischemic Risk After Percutaneous Coronary Intervention
Joo-Young Hahn | Samsung Medical Center, Seoul, South Korea

RESULTS: Clopidogrel monotherapy was superior to aspirin monotherapy in reducing the cumulative incidence of MACCE following PCI and DAPT without an apparent increase in the risk of bleeding.

• SMART-CHOICE 3 published in The Lancet
• ClinicalTrials ID: NCT04418479